At a Glance
- Company: AstraZeneca and Dizal Pharmaceutical
- Location: China
- Deal value: Up to $1.5 billion, including $600 million upfront plus milestones
- Focus area: EGFR exon 20 insertion non-small cell lung cancer
- Next steps: AstraZeneca gains worldwide development and commercial rights while Dizal seeks first-line expansion
What happened?
AstraZeneca agreed to license global rights to Dizal Pharmaceutical’s marketed lung cancer drug Zegfrovy, also known as sunvozertinib. The deal is valued at up to $1.5 billion and gives AstraZeneca worldwide development and commercialisation rights.
Why does it matter?
The transaction strengthens AstraZeneca’s position in EGFR-driven non-small cell lung cancer, a major oncology market. It also reflects strong interest in oral targeted drugs with biomarker-defined patient groups and late-stage clinical data.
Who’s behind it?
AstraZeneca is expanding its oncology footprint through an external licensing deal, while Dizal Pharmaceutical is the China-origin developer of Zegfrovy. The drug is already approved in the U.S. and China for EGFR exon 20 insertion NSCLC after prior systemic therapy.
How was it achieved?
The agreement follows positive phase 3 data from Dizal’s WU-KONG28 trial, which supports expansion into first-line treatment. Breakthrough Therapy designations have also been granted in the first-line setting, adding regulatory momentum to the programme.
What’s next?
Dizal is pursuing first-line expansion, while AstraZeneca will take over global development and commercialisation. The deal effectively brings Dizal’s exon 20 programme into AstraZeneca’s broader oncology portfolio.